A phase 2 trial of BioDiem's seasonal live attenuated influenza vaccine (LAIV) in European adults.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2010
At a glance
- Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BioDiem; Nobilon International
- 26 Feb 2010 Results from this trial are expected later in 2010, according to a BioDiem media release.
- 13 Oct 2009 Status changed from planning to recruiting according to a Schering-Plough media release.
- 13 Oct 2009 A schering-Plough media release reported that the first patient was successfully dosed.